Proteomic Biomarker Identification in Cerebrospinal Fluid for Leptomeningeal Metastases with Neurological Complications.
Adv Exp Med Biol
; 974: 85-96, 2017.
Article
in En
| MEDLINE
| ID: mdl-28353226
ABSTRACT
Leptomeningeal metastases (LM) from solid tumours, lymphoma and leukaemia are characterized by multifocal neurological deficits with a high mortality rate. Early diagnosis and initiation of treatment are essential to kerb neurological deterioration. However, this is not always possible as 25% of cerebrospinal fluid samples produce false-negative results at first cytological examination. The identification of biomarkers that allow stratification of individuals according to risk for developing LM would be a major benefit. Proteomic-based approaches are now in increasing use for this purpose, and these are reviewed in this chapter with a focus on cerebrospinal fluid (CSF) analyses. The construction of a CSF proteome disease database would also facilitate analysis of other neurological disorders.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma
/
Biomarkers, Tumor
/
Cerebrospinal Fluid Proteins
/
Proteomics
/
Meningeal Neoplasms
/
Neoplasm Proteins
Type of study:
Diagnostic_studies
/
Etiology_studies
/
Prognostic_studies
/
Screening_studies
Limits:
Humans
Language:
En
Journal:
Adv Exp Med Biol
Year:
2017
Document type:
Article
Affiliation country: